Apaziquone exposure for 1 h yielded MTT growth inhibition IC50 values of 1.11 ± 0.09 µM in RT112 human bladder carcinoma cells. In EJ138 human bladder carcinoma cells, the same exposure duration yielded an IC50 of 0.915 ± 0.291 µM. In AMOS III, exposure to Apaziquone for 48 hours yielded a reported LD50 of 500nM. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Apaziquone growth inhibition in RT112 bladder carcinoma cells
Cell-based study · RT112 human bladder carcinoma cell lines [1]
RT112 human bladder carcinoma cells were exposed to Apaziquone for 1 h. Growth inhibition measured using the MTT assay yielded an IC50 of 1.11 ± 0.09 µM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10–0.196 µM
- Exposure duration
- Cells were exposed to apaziquone for 1 h
- Method
- media containing a range of apaziquone concentrations
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Apaziquone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Cell lines and chemosensitivity studies (S8, S9, S11, S12, S13, S14, S16); Results > Response of EJ138 and RT112 cells to apaziquone (S36)
growth inhibition determination using the MTT assay: growth inhibition determination using the MTT assay; comparator: control cells — Materials and methods > Cell lines and chemosensitivity studies (S13); Results > Response of EJ138 and RT112 cells to apaziquone (S36)
Apaziquone response in AMOS III
Cell-based study · AMOS III [2]
AMOS III was exposed to Apaziquone-containing media for 48 hours. The reported LD50 was 500nM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5nM to100μM
- Exposure duration
- 48 hours
- Method
- media containing apaziquone
- Reported limits
- Not stated in the sentences used: vehicle, control.
Methods and source locations
Compound reported in the paper: Apaziquone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > In vitro LD50 measurements for Apaziquone (S15, S17, S18); Results > Effect of apaziquone on oral cancer cells (S55)
LD50: LD50 — Materials and Methods > In vitro LD50 measurements for Apaziquone (S15); Results > Effect of apaziquone on oral cancer cells (S55)
Apaziquone growth inhibition in EJ138 bladder carcinoma cells
Cell-based study · EJ138 human bladder carcinoma cell lines [1]
EJ138 human bladder carcinoma cells were exposed to Apaziquone for 1 h. Growth inhibition measured using the MTT assay yielded an IC50 of 0.915 ± 0.291 µM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10–0.196 µM
- Exposure duration
- Cells were exposed to apaziquone for 1 h
- Method
- media containing a range of apaziquone concentrations
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Apaziquone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Cell lines and chemosensitivity studies (S8, S9, S11, S12, S13, S14, S16); Results > Response of EJ138 and RT112 cells to apaziquone (S36)
growth inhibition determination using the MTT assay: growth inhibition determination using the MTT assay; comparator: control cells — Materials and methods > Cell lines and chemosensitivity studies (S13); Results > Response of EJ138 and RT112 cells to apaziquone (S36)